DK2383284T3 - Peptidsekvenser og sammensætninger - Google Patents
Peptidsekvenser og sammensætninger Download PDFInfo
- Publication number
- DK2383284T3 DK2383284T3 DK11157382.0T DK11157382T DK2383284T3 DK 2383284 T3 DK2383284 T3 DK 2383284T3 DK 11157382 T DK11157382 T DK 11157382T DK 2383284 T3 DK2383284 T3 DK 2383284T3
- Authority
- DK
- Denmark
- Prior art keywords
- drb1
- polypeptide
- seq
- influenza
- hla
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (13)
1. Polypeptid, der består af ikke mere end 100 aminosyrer, hvilket polypeptid omfatter én eller flere sekvenser af SEQ ID NO: 3 og/eller én eller flere sekvenser, der har mindst 85 % homologi med den 21. aminosyresekvens ifølge SEQ ID NO: 3: SEQ ID NO: 3 DLIFLARSALILRGSVAHKSC hvor polypeptidet er immunogent i et hvirveldyr, der udtrykker en større histokompatibilitetskompleks-(MHC)-allel, og hvor polypeptidet er immunogent over for en flerhed af influenzavirusstammer.
2. Polypeptid ifølge krav 1, hvilket polypeptid endvidere omfatter: én eller flere sekvenser, der har mindst 85 % homologi med den fulde aminosyresekvens af en hvilket som helst af SEQ ID NO: 1, 2 og 4-6: SEQ ID NO: 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP SEQ ID NO: 2 LLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHS SEQ ID NO: 4 PGIADIEDLTLLARSMVWRP SEQ ID NO: 5 LLIDGTASLSPGMMMGMFNMLSTVLGVSILNLGQ SEQ ID NO: 6 IIGILHLILWILDRLFFKCIYRLF
3. Polypeptid ifølge et hvilket som helst af de foregående krav, hvilket polypeptid omfatter en cytotoksisk T-lymfocyt- (CTL) epitop, og/eller er immunogent til en epitop i sekvensen SEQ ID NO: 3, og/eller endvidere omfatter én eller flere sekvenser fra et influenzavirusprotein, fortrinsvis hvor når polypeptidet er mindst 85 % homologt med den 21. aminosyresekvens ifølge SEQ ID NO: 3, proteinet er et influenza NP-protein, og/eller hvor homologien er 100 %, og/eller hvor polypeptidet består af ikke mere end 50 aminosyrerester.
4. Polypeptidsammensætning, der omfatter to eller flere polypeptider som defineret ifølge et hvilket som helst af de foregående krav.
5. Polypeptidsammensætning ifølge krav 4, der endvidere omfatter én eller flere sekvenser, der består af ikke mere end 100 aminosyrer, hvilke sekvenser omfatter: en sekvens, der har mindst 85 % homologi med den fulde aminosyresekvens ifølge en hvilket som helst af SEQ ID NO: 1, 2 og 4-6: SEQ ID NO: 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP SEQ ID NO: 2 LLYCLMVMYLNPGNYSMQVKLGTLCALCEKQASHS SEQ ID NO: 4 PGIADIEDLTLLARSMVWRP SEQ ID NO: 5 LLIDGTASLSPGMMMGMFNMLSTVLGVSILNLGQ SEQ ID NO: 6 IIGILHLILWILDRLFFKCIYRLF fortrinsvis hvori polypeptider med sekvenserne SEQ ID NO: 1, 3, 4 og 6 alle er til stede, og fortrinsvis hvori polypeptider med sekvenserne SEQ ID NO: 1-6 alle er til stede.
6. Polypeptid, eller polypeptidsammensætning, som defineret ifølge et hvilket som helst af de foregående krav til anvendelse i medicin.
7. Fremgangsmåde til fremstilling af et polypeptid som defineret ifølge et hvilket som helst af de foregående krav, hvilken fremgangsmåde omfatter kombinering af to eller flere sekvenser for at danne polypeptidet.
8. Polypeptidkonstrukt, der består af ikke mere end 100 aminosyrer, hvilket konstrukt omfatter et polypeptid som defineret ifølge et hvilket som helst af de foregående krav blandet med en bærer, hvor bæreren er et hjælpestof og/eller en excipiens.
9. Fremgangsmåde til fremstilling af et polypeptidkonstrukt som defineret ifølge krav 8, hvilken fremgangsmåde omfatter kombinering af to eller flere sekvenser og/eller et polypeptid og blanding med bæreren.
10. Medikament eller vaccinesammensætning mod influenza, der omfatter et polypeptid, eller en polypeptidsammensætning som defineret ifølge et hvilket som helst af de foregående krav, og eventuelt en/et passende excipiens og/eller hjælpestof.
11. Fremgangsmåde til fremstilling af et medikament eller vaccinesammensætning som defineret ifølge krav 10, hvilken fremgangsmåde omfatter blanding af et polypeptid, eller en polypeptidsammensætning som defineret ifølge et hvilket som helst af kravene 1-6 med en/et passende excipiens og/eller hjælpestof.
12. Anvendelse af et polypeptid, en polypeptidsammensætning, et polypeptidkonstrukt eller et medikament eller vaccinesammensætning som defineret ifølge et hvilket som helst af de foregående krav i fremstilling af et medikament eller en vaccine, der er effektiv(t) til behandling eller forebyggelse af influenza.
13. Polypeptid, polypeptidkonstrukt, fremgangsmåde, medikament, vaccine eller anvendelse ifølge et hvilket som helst af de foregående krav, hvor influenzaen er en influenza A-stamme eller influenzaen er en influenza B-stamme.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0602416A GB0602416D0 (en) | 2006-02-07 | 2006-02-07 | Peptide sequences and compositions |
GBGB0613977.8A GB0613977D0 (en) | 2006-02-07 | 2006-07-13 | Peptide sequences and compositions |
EP07712678A EP1991563B1 (en) | 2006-02-07 | 2007-02-05 | Peptide sequences and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2383284T3 true DK2383284T3 (da) | 2016-12-12 |
Family
ID=38109631
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11157382.0T DK2383284T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK11157383.8T DK2383285T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK07712678.7T DK1991563T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK17180723.3T DK3263589T5 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11157383.8T DK2383285T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK07712678.7T DK1991563T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK17180723.3T DK3263589T5 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
Country Status (23)
Country | Link |
---|---|
US (10) | US8475802B2 (da) |
EP (6) | EP3320918A3 (da) |
JP (1) | JP5603551B2 (da) |
KR (1) | KR20080100441A (da) |
CN (3) | CN102382179B (da) |
AP (1) | AP2646A (da) |
AT (1) | ATE534660T1 (da) |
AU (1) | AU2007213562A1 (da) |
BR (1) | BRPI0707543B8 (da) |
CA (1) | CA2641602A1 (da) |
DK (4) | DK2383284T3 (da) |
EA (1) | EA017387B1 (da) |
ES (4) | ES2635590T3 (da) |
GB (1) | GB0613977D0 (da) |
HK (1) | HK1249115A1 (da) |
IL (2) | IL193232A (da) |
MX (1) | MX2008010113A (da) |
NO (1) | NO20083416L (da) |
NZ (1) | NZ570553A (da) |
PL (4) | PL2383284T3 (da) |
PT (1) | PT1991563E (da) |
SG (1) | SG169392A1 (da) |
WO (1) | WO2007091030A2 (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0716992D0 (en) * | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
BRPI0815008B8 (pt) | 2007-08-02 | 2021-05-25 | Biondvax Pharmaceuticals Ltd | vacinas multiméricas com múltiplos epítopos contra influenza |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US8821885B2 (en) | 2007-08-27 | 2014-09-02 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
WO2009085355A2 (en) | 2007-10-01 | 2009-07-09 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
GB0719526D0 (en) | 2007-10-05 | 2007-11-14 | Isis Innovation | Compositions and methods |
EP2072529A1 (en) * | 2007-12-21 | 2009-06-24 | basisnote AG | MHC rapid assay used for the customization of odours |
FR2962739B1 (fr) * | 2010-07-13 | 2014-01-31 | Univ Claude Bernard Lyon | Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza |
AU2011360572B2 (en) | 2011-02-22 | 2017-03-02 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
WO2013093514A2 (en) * | 2011-12-23 | 2013-06-27 | Retroscreen Virology Ltd | Vaccines - peptides |
CA2970211A1 (en) * | 2014-12-10 | 2016-06-16 | Vaxsia Biomedical Inc. | Novel protein structure produced by effective antibody used for immunization |
WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
CN106310214A (zh) * | 2015-06-30 | 2017-01-11 | 中国科学院上海巴斯德研究所 | 流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用 |
JP2019064924A (ja) * | 2016-02-24 | 2019-04-25 | Agc株式会社 | インフルエンザワクチン |
KR101888751B1 (ko) * | 2016-09-22 | 2018-09-21 | 이화여자대학교 산학협력단 | 인플루엔자 b 백신 |
WO2018126060A1 (en) | 2016-12-28 | 2018-07-05 | Invvax, Inc. | Influenza vaccines |
AU2018388102A1 (en) | 2017-12-21 | 2020-07-16 | Green Biomed, Inc. | Cross-immunizing antigen vaccine and method for preparation thereof |
US20230295582A1 (en) * | 2020-07-21 | 2023-09-21 | Flugen, Inc. | Influenza virus backbone |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4981782A (en) | 1987-05-14 | 1991-01-01 | Sri International | Synthetic peptides for diagnosis and prevention of influenza virus infection and their use |
US5741493A (en) * | 1991-01-24 | 1998-04-21 | Pasteur Merieux Serums Et Vaccins | Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive |
IL101639A0 (en) * | 1992-04-17 | 1992-12-30 | Yeda Res & Dev | Recombinant influenza vaccines |
DE69334076D1 (de) * | 1992-08-07 | 2006-11-30 | Pharmexa Inc | Hla bindepeptide und ihre verwendungen |
US20040087521A1 (en) * | 1993-03-18 | 2004-05-06 | Merck & Co., Inc. | Nucleic acid pharmaceuticals-influenza matrix |
IL109664A0 (en) | 1993-05-18 | 1994-08-26 | Rijksuniversiteit | Peptides of human influenza virus for use in human t cell response inducing compositions |
US6939546B2 (en) | 1993-05-21 | 2005-09-06 | The United States Of America As Represented By The Secretary Of The Army | Model for testing immunogenicity of peptides |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
AU3727895A (en) | 1994-09-30 | 1996-04-26 | St. Jude Children's Research Hospital | Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus |
US7269219B1 (en) * | 1997-02-14 | 2007-09-11 | At&T Corp. | Non-linear quantizer for video coding |
IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
JP2001151698A (ja) * | 1999-09-10 | 2001-06-05 | Nichiko Pharmaceutical Co Ltd | インフルエンザワクチン |
WO2002026252A1 (fr) | 2000-08-10 | 2002-04-04 | Tsinghua University | Vaccin contre le virus de la grippe et son procede de preparation |
ES2327103T3 (es) * | 2000-09-25 | 2009-10-26 | Polymun Scientific Immunbiologische Forschung Gmbh | Vacuna viva de influenzavirus y procedimiento de fabricacion. |
US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
US20050013826A1 (en) * | 2002-12-20 | 2005-01-20 | Shneider Alexander M. | Vaccine compositions and methods |
EP1597400B8 (en) * | 2003-02-25 | 2013-10-09 | MedImmune, LLC | Methods of producing influenza vaccine compositions |
EP1603590A4 (en) | 2003-03-07 | 2008-08-27 | Merck & Co Inc | INFLUENZA VIRUS VACCINE |
US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
DE102004052026B4 (de) * | 2003-11-07 | 2015-08-27 | Totankako Co., Ltd. | Kollektor |
FR2863758B1 (fr) * | 2003-12-11 | 2006-07-14 | Centre Nat Rech Scient | Cellule de commande electronique pour diode electroluminescente organique d'afficheur a matrice active, procedes de fonctionnement et afficheur |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
US20060024670A1 (en) | 2004-05-18 | 2006-02-02 | Luke Catherine J | Influenza virus vaccine composition and methods of use |
WO2006116082A1 (en) * | 2005-04-21 | 2006-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US20070116717A1 (en) | 2005-08-01 | 2007-05-24 | Shneider Alexander M | Influenza vaccine compositions and methods |
JP5198290B2 (ja) | 2006-02-02 | 2013-05-15 | グローブイミューン,インコーポレイテッド | 免疫反応を誘発する酵母ベースワクチン |
GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
-
2006
- 2006-07-13 GB GBGB0613977.8A patent/GB0613977D0/en not_active Ceased
-
2007
- 2007-02-05 EP EP17210264.2A patent/EP3320918A3/en active Pending
- 2007-02-05 ES ES11157383.8T patent/ES2635590T3/es active Active
- 2007-02-05 BR BRPI0707543A patent/BRPI0707543B8/pt active IP Right Grant
- 2007-02-05 AP AP2008004571A patent/AP2646A/xx active
- 2007-02-05 PL PL11157382T patent/PL2383284T3/pl unknown
- 2007-02-05 EP EP17180723.3A patent/EP3263589B1/en active Active
- 2007-02-05 DK DK11157382.0T patent/DK2383284T3/da active
- 2007-02-05 CN CN201110311189.2A patent/CN102382179B/zh active Active
- 2007-02-05 NZ NZ570553A patent/NZ570553A/xx unknown
- 2007-02-05 CA CA002641602A patent/CA2641602A1/en not_active Abandoned
- 2007-02-05 EA EA200870237A patent/EA017387B1/ru not_active IP Right Cessation
- 2007-02-05 US US12/278,728 patent/US8475802B2/en active Active
- 2007-02-05 SG SG201100861-2A patent/SG169392A1/en unknown
- 2007-02-05 CN CN201210252429.0A patent/CN102807608B/zh active Active
- 2007-02-05 EP EP11157383.8A patent/EP2383285B1/en active Active
- 2007-02-05 MX MX2008010113A patent/MX2008010113A/es active IP Right Grant
- 2007-02-05 ES ES11157382.0T patent/ES2611034T3/es active Active
- 2007-02-05 DK DK11157383.8T patent/DK2383285T3/da active
- 2007-02-05 CN CN2007800079350A patent/CN101395176B/zh active Active
- 2007-02-05 EP EP07712678A patent/EP1991563B1/en not_active Revoked
- 2007-02-05 WO PCT/GB2007/000383 patent/WO2007091030A2/en active Application Filing
- 2007-02-05 KR KR1020087021658A patent/KR20080100441A/ko not_active Application Discontinuation
- 2007-02-05 DK DK07712678.7T patent/DK1991563T3/da active
- 2007-02-05 DK DK17180723.3T patent/DK3263589T5/da active
- 2007-02-05 ES ES07712678T patent/ES2374841T3/es active Active
- 2007-02-05 EP EP11157382.0A patent/EP2383284B1/en active Active
- 2007-02-05 PL PL17180723T patent/PL3263589T3/pl unknown
- 2007-02-05 AT AT07712678T patent/ATE534660T1/de active
- 2007-02-05 EP EP19192958.7A patent/EP3620463A1/en active Pending
- 2007-02-05 JP JP2008553817A patent/JP5603551B2/ja active Active
- 2007-02-05 PL PL07712678T patent/PL1991563T3/pl unknown
- 2007-02-05 PT PT07712678T patent/PT1991563E/pt unknown
- 2007-02-05 PL PL11157383T patent/PL2383285T3/pl unknown
- 2007-02-05 AU AU2007213562A patent/AU2007213562A1/en not_active Abandoned
- 2007-02-05 ES ES17180723T patent/ES2790730T3/es active Active
-
2008
- 2008-08-04 IL IL193232A patent/IL193232A/en active IP Right Grant
- 2008-08-04 NO NO20083416A patent/NO20083416L/no not_active Application Discontinuation
-
2012
- 2012-05-07 US US13/465,940 patent/US8444995B2/en active Active
-
2013
- 2013-05-30 US US13/906,232 patent/US9446116B2/en active Active
-
2016
- 2016-08-08 US US15/231,347 patent/US9889191B2/en active Active
-
2017
- 2017-04-23 IL IL251867A patent/IL251867B/en active IP Right Grant
-
2018
- 2018-01-08 US US15/865,214 patent/US10279032B2/en active Active
- 2018-01-22 US US15/876,781 patent/US10335480B2/en active Active
- 2018-07-03 HK HK18108547.1A patent/HK1249115A1/zh unknown
-
2019
- 2019-03-07 US US16/295,488 patent/US10765734B2/en active Active
- 2019-08-14 US US16/540,811 patent/US20190365883A1/en not_active Abandoned
-
2020
- 2020-09-04 US US17/013,000 patent/US11439702B2/en active Active
-
2022
- 2022-09-09 US US17/931,017 patent/US20230233660A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11439702B2 (en) | Influenza peptides and compositions | |
EP2004676B1 (en) | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof | |
AU2013201008C1 (en) | Peptide sequences and compositions |